Qualigen Appoints Donald W. Grimm to its Board of Directors

Strategic Insights -

Donald W. Grimm, a veteran executive from the pharmaceutical, biotechnology, and medical device industries, has joined Qualigen's Board of Directors. With a distinguished career spanning over three decades, Grimm brings a wealth of expertise to the company. His most notable achievements include leading Hybritech, Inc. to a significant revenue growth of $150 million, developing the Prostate Specific Antigen (PSA) diagnostic test, and serving as President, CEO, and Chairman of various companies.

Key Takeaways:

  • Donald W. Grimm joins Qualigen's Board of Directors, bringing over 30 years of experience in the pharmaceutical, biotechnology, and medical device industries.
  • Grimm's career highlights include leading Hybritech, Inc. to a revenue growth of $150 million, developing the Prostate Specific Antigen (PSA) diagnostic test, and serving as President, CEO, and Chairman of various companies.
  • Qualigen anticipates FDA approval and U.S. launch of its first product, a diagnostic blood test for total prostate specific antigen (Total PSA), with two other prostate cancer-related diagnostic tests scheduled for introduction later this year.
  • Grimm has served on the boards of Ablation Technologies, Bioreason, eStudySite.com, Invitrogen, BioQ.com, and Multiple Peptide Systems, and is a consultant to Structural Bioinformatics.
  • Qualigen's FastPack System, a proprietary point-of-care blood testing system, has been launched in Europe and represents a worldwide market opportunity of over $1.9 billion annually.

Statistics:

  • Qualigen's FastPack System has been launched in Europe.
  • The FastPack System represents a worldwide market opportunity of over $1.9 billion annually.
  • Hybritech, Inc. under Grimm's leadership grew to $150 million in revenue.
  • Grimm has over 30 years of experience in the pharmaceutical, biotechnology, and medical device industries.
  • Qualigen anticipates FDA approval and U.S. launch of its first product, a diagnostic blood test for total prostate specific antigen (Total PSA), with two other prostate cancer-related diagnostic tests scheduled for introduction later this year.

Sources:

  • Qualigen, Inc. press release (June 27)